ARCA biopharma Files 8-K for Material Agreement

Ticker: ORKA · Form: 8-K · Filed: Aug 15, 2024 · CIK: 907654

Arca Biopharma, Inc. 8-K Filing Summary
FieldDetail
CompanyArca Biopharma, Inc. (ORKA)
Form Type8-K
Filed DateAug 15, 2024
Risk Levelmedium
Pages8
Reading Time10 min
Key Dollar Amounts$300,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, filing

TL;DR

ARCA bio filed an 8-K for a material agreement. Keep an eye on this one.

AI Summary

ARCA biopharma, Inc. filed an 8-K on August 15, 2024, reporting an entry into a material definitive agreement and financial statements. The filing details the company's principal executive offices located at 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021. The report was filed as of August 15, 2024, with the earliest event reported on August 14, 2024.

Why It Matters

This 8-K filing indicates ARCA biopharma has entered into a significant agreement, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.

Key Players & Entities

  • ARCA biopharma, Inc. (company) — Registrant
  • August 14, 2024 (date) — Earliest event reported
  • August 15, 2024 (date) — Date of report
  • 10170 Church Ranch Way Suite 100 (address) — Principal Executive Offices
  • Westminster, Colorado (location) — Principal Executive Offices
  • 80021 (zip_code) — Principal Executive Offices

FAQ

What type of material definitive agreement did ARCA biopharma enter into?

The filing states an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on August 14, 2024.

What is the principal executive office address for ARCA biopharma, Inc.?

The principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.

What is the Commission File Number for ARCA biopharma, Inc.?

The Commission File Number for ARCA biopharma, Inc. is 000-22873.

What are the previous names of ARCA biopharma, Inc.?

The company was formerly known as NUVELO INC (name change effective February 3, 2003) and HYSEQ INC (name change effective June 10, 1997).

Filing Stats: 2,444 words · 10 min read · ~8 pages · Grade level 20 · Accepted 2024-08-15 16:15:35

Key Financial Figures

  • $300,000 — exchange for a one-time cash payment of $300,000 (the " Transaction "). The closing of t

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: August 15, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.